AstraZeneca
Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance
September 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Lung Ambition Alliance, lung cancer, oncology, pharma
Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
Top Ten most popular articles on Pharmafile.com this week
September 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit
It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …
AZ’s Tagrisso secures China approval in first-line advanced lung cancer
September 4, 2019Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma
AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …
AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk
September 2, 2019Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma
AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …
AstraZeneca lupus drug makes comeback to meet main goal at Phase 3
August 29, 2019Research and Development AstraZeneca, Lupus, anifrolumab, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …
AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer
August 21, 2019Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure
August 20, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga
New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …
Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations
August 14, 2019Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …
AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
August 9, 2019Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …
AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers
July 26, 2019Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma
NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …
Top Ten most popular articles on Pharmafile.com this week!
July 19, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMAL Therapeutics, Alzheimer's Ebola, Amgen, AstraZeneca, EMA, FDA, Novartis, pharma
On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 …
AstraZeneca to switch entire fleet to electric vehicles by 2030
July 17, 2019Research and Development AstraZeneca, EV100, electric vehicles, environmentalism, pharma, renewables
AstraZeneca has revealed plans to use only electric vehicles by 2030. In joining the EV100 group, AstraZeneca will transfer the …
AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes
July 15, 2019Sales and Marketing AstraZeneca, EMA, FDA, US, diabetes, farxiga
The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in …
AstraZeneca’s Imfinzi gets orphan drug designation from FDA
July 12, 2019Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
